Takeda, Motus GI & more — 5 GI company key notes

Here are five updates on GI companies from the past week:

Takeda Pharmaceutical submitted a voluntary conditional takeover bid to purchase 100 percent of TiGenix, a biopharmaceutical company developing stem cell therapies for anti-inflammatory disease, for $628 million.

Motus GI Holdings, a medical device company, filed a $29 million initial public offering with the Securities Exchange Commission Jan. 5.

Exact Sciences expects to report net sales between $86.9 million and $87.9 million in its fourth quarter fiscal year 2017 results, raising the company's year-round revenues to between $265.5 million and $266.5 million.

OrphoMed, a clinical-stage biopharmaceutical company, named Mark Sostek, MD, its next CMO.

More articles on gastroenterology: 
Motus GI files for $29M initial public offering — 3 insights
GI leader to know: Dr. Donnie Smith of GI Associates of West Alabama
Exact Sciences to increase sales force by 200 employees in revenue boosting move — 5 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months